Highlights:

  • Island Pharmaceuticals (ASX:ILA) was trading at AUD 0.48, up 5.43% during the afternoon Trading session on 21 August 2026.
  • The company commissioned a second GMP-grade Galidesivir Manufacturing campaign with PI Health Sciences.
  • Island expects to have approximately 700–800 treatment courses of Galidesivir available in Q4 CY26.
  • The ongoing Bundibugyo Ebola outbreak has recorded 5,208 confirmed cases and 2,476 deaths as at 18 August 2026.
  • Galidesivir deployment in Uganda is expected during CY26 under the WHO-recognised MEURI framework.

Island Pharmaceuticals Limited (ASX:ILA) has commissioned a second manufacturing campaign for GMP-grade Galidesivir, expanding the company’s available antiviral inventory as it progresses its outbreak response and biodefence strategy.

The additional production campaign is being undertaken with PI Health Sciences (PIHS), a global contract research, development and manufacturing organisation, and is designed to increase the Supply of Galidesivir available for potential deployment during active outbreaks and broader government and biodefence opportunities.

Island Pharmaceuticals was trading at AUD 0.48, up 5.43% during the afternoon trading session on 21 August 2026. The company’s shares remain up 110.87% over the past year.

Additional Galidesivir Manufacturing Campaign Begins

Island Pharmaceuticals said the second GMP manufacturing campaign will materially expand its available Galidesivir inventory.

Following completion of the new manufacturing campaign, together with previously commissioned supply, the company expects to have approximately 700 to 800 treatment courses available during Q4 CY26.

The company said maintaining a larger inventory position provides flexibility to support active outbreak responses, government engagement, potential procurement opportunities and regulatory initiatives without requiring a new manufacturing cycle each time a potential requirement emerges.

The additional manufacturing follows Island’s initial engagement with PIHS and the company’s opportunity to provide Galidesivir on a compassionate use basis for patients infected with Bundibugyo Ebola virus in Uganda under the World Health Organization-recognised Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework.

Bundibugyo Ebola Outbreak Highlights Need for Supply Availability

Island’s decision to increase Galidesivir inventory comes as the ongoing Bundibugyo Ebola outbreak continues to spread across Central Africa, including the Democratic Republic of Congo and Uganda.

As at 18 August 2026, the outbreak had recorded 5,208 confirmed cases and 2,476 deaths, representing a case-fatality rate of 47.5%.

The company noted that the Bundibugyo strain currently has no approved therapeutic treatment or vaccine.

Island said the availability of GMP-grade Galidesivir could support its ability to respond to active outbreak situations while also providing opportunities to generate human efficacy, safety and virological data through deployment activities.

Uganda Program May Generate Human Data

Island Pharmaceuticals expects Galidesivir to be deployed in Uganda during CY26 under the MEURI framework.

The program is intended to provide an opportunity to use Galidesivir during an active Ebola outbreak and potentially generate prospective human efficacy, safety and virological data.

The company said this activity complements its existing development pathway for potential approval of Galidesivir for Marburg under the FDA’s Animal Rule.

Island is pursuing a dual development strategy for Galidesivir, focusing on outbreak response, biodefence applications and regulatory pathways.

Management Highlights Broader Galidesivir Strategy

Island Pharmaceuticals CEO and Managing Director Dr David Foster said the decision to commission additional GMP-grade Galidesivir reflects progress across the program and the increasing number of opportunities available.

Dr Foster said the expected inventory of around 700–800 treatment courses before the end of CY26 provides the company with flexibility to pursue opportunities without starting a new manufacturing campaign each time.

He added that maintaining a meaningful inventory strengthens engagement with governments, biodefence agencies and potential partners involved in outbreak preparedness, procurement and stockpiling.

Galidesivir Development Pathway Expands Beyond Ebola

Island Pharmaceuticals is developing Galidesivir as a broad-spectrum antiviral and biodefence countermeasure.

The company stated that Galidesivir has demonstrated activity across more than 20 RNA viruses, including Ebola, Marburg, MERS, Zika and Yellow Fever.

Island’s development pathway includes the potential use of the FDA Animal Rule, a regulatory framework allowing approvals based on controlled non-human primate efficacy studies when human trials are not feasible.

The company also highlighted its ongoing work across Ebola and Marburg programs as part of its broader strategy.

Investor Takeaway

Island Pharmaceuticals’ latest update focuses on increasing the availability of GMP-grade Galidesivir through a second manufacturing campaign, with the company targeting approximately 700–800 treatment courses by Q4 CY26.

The expanded inventory is intended to support potential outbreak deployment, regulatory engagement and biodefence opportunities, while the Uganda MEURI program may provide human safety, efficacy and virological data.

Investors may continue to monitor manufacturing progress, deployment activities, regulatory milestones and developments across the company’s Galidesivir program.